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mann).Substantial progress in functional genomic and proteomic technologies has opened new perspec-
tives in biomedical research. The sequence of the human genome has been mostly determined
and opened new visions on its complexity and regulation. New technologies, like RNAi and protein
arrays, allow gathering knowledge beyond single gene analysis. Increasingly, biological processes
are studied with systems biological approaches, where qualitative and quantitative data of the com-
ponents are utilized to model the respective processes, to predict effects of perturbations, and to
then reﬁne these models after experimental testing. Here, we describe the potential of applying
functional genomics and proteomics, taking the ERBB family of growth-factor receptors as an exam-
ple to study the signaling network and its impact on cancer.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. The role of the ERBB-signaling network in cancer
Receptor tyrosine kinases (RTKs) play essential roles in the
transduction of external stimuli and enable cells to properly re-
spond to their environment. The epidermal growth-factor receptor
(EGFR) family belongs to the RTK family and is expressed in various
tissues, e.g. of epithelial, mesenchymal and neuronal origin [1]. The
EGFR family has received a huge amount of attention in the past
few years, mostly in the context of cancer. Originally named as
v-erbB, due to their homology to the erythroblastoma viral gene
product, the ERBB (or EGFR) family of proteins consists of four
receptors (ERBB1-4) that have 13 polypeptide ligands sharing a
conserved EGF domain [2]. Upon ligand binding, the ERBB family
of receptor tyrosine kinases form homo- and/or heterodimers,
and activate downstream signaling pathways. Out of the four ERBB
proteins, the EGFR (or ERBB1) and ERBB4 are autonomous, i.e. they
are able to undergo homodimerization and to transmit the signal
inside the cells, thus regulating cell proliferation, migration, and
differentiation [3]. In contrast, the ERBB2 and ERBB3 proteins are
non-autonomous receptors. ERBB2 lacks the capacity to interact
with any known ligand which is due to its inherent structure [4],
while ERBB3 contains a defective tyrosine kinase domain becausechemical Societies. Published by E
.wiemann@dkfz.de (S. Wie-of amino acid substitutions within critical residues of the active
site [5]. Despite their non-autonomous properties, these proteins
form potent heterodimers with the other family members and help
transduce signals to the interior of the cell.
In cancer, ERBB receptor family members, especially EGFR and
ERBB2, are frequently dysregulated through gene ampliﬁcation,
overexpression, deletions, or mutations. For example, EGFR is over-
expressed in almost 80% of head and neck cancers [6], whereas
deletions have been observed in the different parts of the EGFR
protein mainly in brain tumors [7]. Furthermore, in non-small-cell
lung carcinoma (NSCLC), mutations on the tyrosine kinase domain
of the EGF receptor have been found in the sub-populations of the
patients who do respond to treatment with geﬁtinib/Iressa [8]. In
case of the ERBB2 receptor, gene ampliﬁcations result in overex-
pression of the protein product especially in breast cancer, where
almost 30% of the patients are affected [9]. Ampliﬁcations of the
ERBB2 receptor gene have been further reported for other cancers
like ovarian cancers, however, the prevalence that has been re-
ported there varies from between 8% and 66% in different studies
[10]. In few cases, mutations in the tyrosine kinase domain of the
ERBB2 have been identiﬁed in some non-small cell lung carcino-
mas (NSCLC) [11]. Due to their dysregulation in different types of
cancer, the high incidence and the membrane localization, EGFR
and ERBB2 have been within the focus of targeted therapies for
more than a decade. Currently, there are two types of targeting ap-
proaches. One is the use of monoclonal humanized or chimericlsevier B.V. All rights reserved.
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cell surface due to their accessibility to circulating antibodies.
Trastuzumab/Herceptin was the ﬁrst FDA-approved (in 1998)
monoclonal antibody to target overexpressed ERBB2 in breast can-
cer. Cetuximab/Erbitux is a chimeric antibody targeting EGFR and
was approved in 2003 for the treatment of colorectal cancer. The
second approach is the use of small chemical inhibitors that specif-
ically compete for the ATP binding sites of the receptors’ tyrosine
kinase domain. For example, geﬁtinib/Iressa and erlotinib/Tarceva,
both of which target the tyrosine kinase domain of EGFR, are ap-
proved for the treatment of NSCLC. Although these treatments
are successful to some extent, de novo or acquired resistance to
these drugs are major causes of failure during therapy. Resistance
may develop due to autocrine or paracrine signaling which can
activate alternative combinations of receptors (receptor heterodi-
mers) or due to compensatory mechanism that cells already have
or develop upon treatment and give them selective advantages.
2. Studying gene and protein networks
2.1. RNA and protein proﬁling
In order to build gene and miRNA regulatory networks, gen-
ome-wide mRNA and miRNA proﬁling are applied using different
expression proﬁling platforms. While the analysis of gene expres-
sion had for long been mostly done with hybridization-based array
technologies [12], this is currently shifting towards direct sequenc-
ing of RNA [13]. The latter technology promises to not only cover a
higher dynamic range of gene expression and to also detect se-
quences that are not represented in the chip-based platforms but
to uncover also the full spectrum of mutations that are increasingly
identiﬁed in tumors [14] and to identify other rearrangements
[15]. These speciﬁcations provide a new level of comprehensive-
ness that had not been possible before and will make high-
throughput RNA-sequencing the method of choice for the analysis
of gene expression and RNA structure. Individual RNA expression
proﬁles are overlaid and changes in the expression of protein cod-
ing genes are compared with those of known or predicted miRNAs
and of other non-protein coding RNAs that potentially regulate the
expression of the corresponding genes. One drawback of this ap-
proach is that target genes are missed where protein expression
is only regulated at the translational level. Therefore, network
analysis should be extended to proﬁling also of protein within
the cells or tissues, since miRNAs are known to inhibit translation
in the case of imperfect complementarity. There, protein arrays
[16] and quantitative mass spectrometry comes into place which
have the additional capacity to also measure the dynamics of phos-
phorylation in signaling pathways [17,18]. Yet other layers of
information are the epigenetic regulation of gene expression and
the chromosomal location of miRNA genes which are also likely
to also inﬂuence the non-transcriptional and physical regulation
of the biological processes and, potentially, also their dysregulation
in cancer.2.2. RNAi and combinatorial RNAi
RNA interference (RNAi) has proven to be a powerful reverse ge-
netic technology to study the function of genes or proteins since its
ﬁrst discovery by Fire and colleagues [19]. It has become the most
practical tool to carry out loss-of-function studies in a high
throughput and is increasingly applied at a genome-wide level in
different organisms to elucidate the function or contribution of
each gene to cellular processes or phenotypes under investigation
[20,21]. In most of these studies, however, RNAi was limited to per-
turbations of only single genes at a time. This setup was not able touncover synergistic or additive effects of several proteins acting in
combination through cross-talking or other, for instance, buffering
effects. To solve this issue, there have been several efforts to pro-
duce multiple knockdowns simultaneously in order to study the
cross-talk of proteins in a given protein network. For this purpose,
we have developed ‘‘combinatorial RNAi” to produce double and
triple knockdowns using chemically synthesized siRNAs [22]. Mea-
suring the knockdown efﬁciencies quantitatively at the mRNA and
protein levels by qRT-PCR and reverse phase protein arrays (RPPA),
respectively, turned out to provide information necessary for the
interpretation of the resulting data. With combinatorial RNAi, we
initially studied the relative contribution of ERBB2 receptor and
its downstream intermediates AKT1 and MEK1 to the invasive phe-
notype of the breast carcinoma cell line HCC1954. Recently, Bakal
et al. extended this approach and produced knockdown of two gi-
ven genes simultaneously in 17,724 combinations to study the reg-
ulators of the Jun NH2-terminal kinase pathway in Drosophila in
order to build a JNK phosphorylation network [23]. Further, there
are studies emerging in which siRNAs are applied together with
approved anticancer drugs to study synergistic or additive effects
on the cancer phenotype of cells. For example, Spankuch et al. used
siRNAs targeting PLK1 (polo-like kinase 1) in combination with
either trastuzumab/Herceptin or paclitaxel and observed that
knockdown of Plk1 increased the sensitivity of cells to both drugs
by inducing G2/M arrest and apoptosis [24]. These and other stud-
ies demonstrate that the combinatorial targeting of molecules
might be a more promising approach than targeting each molecule
at a time.
2.3. Quantitative proteomics – molecular readout
Diverse technologies exist to monitor the outcome, i.e. the in-
duced effects of perturbations. They distinguish molecular and
phenotypic levels at which data is acquired, and this data is then
put in relation to the biological question that should be addressed.
In RNAi, the direct targets of the perturbation are mRNAs of genes
complementary to the respective siRNAs. Consequently, the quan-
titative analysis of residual mRNA levels is commonly used as a
measure of success in the down-regulation of the targeted genes.
There, different kinds of DNA-chips may be utilized for whole-tran-
scriptome analysis of gene expression (especially to examine the
off-target effects of given siRNAs or shRNAs), while quantitative
RT-PCR is mostly applied to speciﬁcally measure the remaining
levels of the targeted mRNA. Since RNAi rarely leads to the com-
plete knockdown of the respective genes, levels of 70–90% knock-
down are commonly accepted as being sufﬁcient to trust RNAi
having been successful. However, it is mostly proteins that convey
the function of a particular gene product. Direct quantiﬁcation of
the targeted proteins and, in many cases, of their activity should
provide more relevant and reliable information than mere mRNA
analysis. The quantiﬁcation of proteins has for long been mostly
done with Western blot analysis, however, this methodology suf-
fers from poor reproducibility and a rather narrow dynamic range.
We and others have established the quantitative protein array
technology [16]. With RPPA, complex cell or tissue lysates are spot-
ted on microchips and individual proteins are then detected and
quantiﬁed using speciﬁc antibodies. In contrast, microspot immu-
no arrays (MIA) are produced by spotting antibodies that capture
their respective target proteins from a complex mixture of proteins
being incubated with these arrays. Bound proteins are then de-
tected with a second speciﬁc antibody that is usually directed
against another epitope of the same protein. Utilization of two spe-
ciﬁc antibodies for every protein on the one hand makes the MIA
technology particularly amenable to quantitative network analysis
as this increases the speciﬁcity of protein detection and allows for
the ﬁne-grained analysis of protein modiﬁcations, such as
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ing events over time [17]. On the other hand, the requirement of
having available two reliable antibodies for every targeted protein
impedes this technology from being applied in high throughput.
We have extended the use of proteinmicroarrays to quantify the
knockdown efﬁciencies following RNAi [22]. For the quantiﬁcation
of residual protein levels we utilized RPPA after the knockdown of
ERBB2 receptor and its downstream proteins AKT1 and MEK1 in
single and multiple knockdown settings. The knockdown efﬁciency
of the respective proteins ranged from 60% to 90% and did not par-
ticularly differ when the proteins had been targeted in single and
multiple knockdowns. In another study, we have combined (combi-
natorial) RNAi and RPPA to study the ERBB receptor-regulated G1/
S-transition network in de novo trastuzumab/Herceptin resistant
breast cancer cell line [25]. In this study, the RPPA technology
was applied in order to quantify the phosphorylation of the retino-
blastoma protein (pRB) as a measure of G1/S transition and, hence,
cell cycle progression. Individual genes or two genes of the ERBB
receptor family were knocked down via (combinatorial) RNAi, and
effects on the activation of pRB and other proteins in the network
were quantiﬁed with speciﬁc antibodies. The results indicated that
c-MYC or the G1 cyclin Cylin D1might be promising targets to over-
come trastuzumab/Herceptin resistance, while members of the
ERBB receptor family were not identiﬁed as suitable targets for
treatment in this in vitro system.
Additional to chip-based microarrays, bead-based array tech-
nologies have been developed that permit the quantiﬁcation of
proteins with help of suspension microarrays that are based on
microspheres and ﬂow cytometry [26]. The microspheres are
loaded with two ﬂuorophores in varying concentrations. This al-
lows to distinguish upto 100 different spectral signatures, enabling
to multiplex the analysis of proteins in complex solutions. Thus far,
the potential of bead-based arrays is mostly discussed for bio-
marker screening in serum proteomics [27], however, applications
in protein network analysis can be envisioned.
2.4. Cellular assays – phenotypic readout
In addition to the molecular read-outs described above, their
reﬂection to the phenotype of cells or of the organism being inves-
tigated has been studied utilizing several cell-based or reporter as-
says after knocking down genes either individually or in
combination, or after overexpression of the respective proteins
via transfection of expression constructs. For the latter, we estab-
lished automated cell-based assays, for example BrdU proliferation
[28] and activated Caspase-3 [29] assays, to study the effects of
overexpressed candidate proteins at a single cell resolution using
ﬂow cytometry or high-content screening microscopy in a high-
throughput manner. In order to study the role of given candidate
proteins in metastasis-related processes, we further implemented
invasion and polyHEMA assays (anchorage-independent growth),
and identiﬁed novel modulators of invasion, such as VMP1 [30].
In another study, we have investigated the contribution of different
signaling intermediates downstream of ERBB2, i.e. AKT1 andMEK1,
by producing single, double and triple knockdowns of these pro-
teins to the invasive phenotype of cells using the invasion assay
with a ﬂow cytometry output [22]. We could show that although
single knockdown of ERBB2 and MEK1 did not affect the invasion
potential of the cells, their combinatorial knockdown decreased
the invasion capacity of the cells. Down regulation of AKT1 had
the strongest effect and, surprisingly, triple knockdown of the all
three proteins was less effective on the invasion of cells than
knockdown of AKT1 alone. This data demonstrated the cross-talk
between different signaling pathways and stressed the require-
ment for a network level study of the proteins involved.3. Modeling the ERBB network
Functional genomics and proteomics feed into systems biology
with large quantities of high-quality data as are prerequisite for
the modeling and, ultimately, understanding at a network level
of the biological processes being analyzed (Fig. 1). While system le-
vel approaches have been used in a biological ﬁeld more than half a
century ago [31], their wide-range application in the analysis of
biological processes is just emerging. The ERBB receptor signaling
network has been in the center of different systems biology studies
in the past few years because of its involvement in several impor-
tant biological processes and its deregulation in diseases, e.g. can-
cer. In general, several models have been proposed that deal with
the dynamics of EGFR endocytosis and the effects of ERBB2 overex-
pression in this process [32,33], effects of receptor co-expression
on the dynamics of dimerization and cellular phenotype [34],
and the activation dynamics of downstream kinases based on dif-
ferent ligands and receptor localization [35,36]. These dynamical
differential equation-based models provided an improved under-
standing of how the ERBB system functions at the molecular level
and have helped to better interpret the effects of molecular and
clinical outcomes of any distortion of these receptors (e.g. overex-
pression of EGFR and/or ERBB2) in cancer. In a different approach,
called partial least-squares regression (PLSR) model, regression of
phospho-protein molecular data to phenotypical data at different
receptor expression levels was utilized to predict the involvement
of different signaling molecules or phosphorylation sites to the cell
proliferation and migration phenotypes of cells [37,38]. Recently,
we employed a Boolean approach to model the ERBB receptor-reg-
ulated G1/S transition of the cell cycle in ERBB2 overexpressing
and trastuzumab/Herceptin resistant HCC1954 cells [25]. In this
study, we constructed a network of ERBB receptors including
downstream kinases, transcription factors and cell cycle proteins
being involved in G1/S transition, and examined the relative con-
tribution of each network component to G1/S transition of the cell
cycle by perturbing each protein individually as well as combina-
tions of receptors using combinatorial RNAi. By combining RNAi
with RPPA we then reverse engineered the network and validated
the known as well as determined novel interactions in the ERBB
protein network. Recently, in an elegant study Jones et al. have ta-
ken a genome-wide approach to study the recruitment of adaptor
proteins to their activated receptors to determine afﬁnity con-
stants, which are mostly the missing quantitative data for differen-
tial equation-based models [39]. In this study, protein microarrays
were utilized covering 106 SH2 and 41 PTB domains that interact
with the phoshotyrosine sites on the ERBB receptors (12 sites on
EGFR, six sites in ERBB2 and 11 sites on ERBB3) to measure the dis-
sociation constants. The study veriﬁed the previously known inter-
actions and identiﬁed many more new biophysical interactions,
and also provided high quality and quantity data for future model-
ing approaches. Most importantly, the authors hypothesized that
the oncogenic potential of EGFR and ERBB2 overexpression stems
from their activation of different pathways rather than stronger
signaling through their primary signaling. For this reason, they
concluded that proteins being involved in this secondary signaling
might serve as more selective targets. Hence, this and similar other
high-throughput approaches will not only provide new insights
into ‘well-known’ protein networks (here: ERBB-signaling net-
work), but also be useful to obtain necessary high-quality quanti-
tative data for more realistic modeling studies as well as form
the basis for new and extended hypotheses.
Importantly, current ERBB protein networks should be ex-
tended by including also negative feedback regulators in order to
obtain a more comprehensive view of the system. Several feedback
regulators, for example c-CBL, MIG-6, and LRIG1, have already been
Fig. 1. From functional genomics and proteomics via systems biology to translational research: Gene/protein networks are constructed based on literature information. Then
tools, e.g. RNAi or overexpression constructs are utilized to perturb the system in single and multiple settings (i.e. combinatorial RNAi) at a genome-wide scale with molecular
and/or phenotypical read-outs. Data is analyzed with robust statistical methods and integrated to generate data-based networks. These are extended with miRNAs and are
thereafter compared with the original literature-based networks. Newly identiﬁed genes/miRNAs as well as connections are validated in animal models and patients samples
for their potential to serve as novel drug targets.
Ö. Sahin, S. Wiemann / FEBS Letters 583 (2009) 1766–1771 1769identiﬁed. The expression of some of these is induced in response
to receptor activation, which in turn restricts ERBB signaling. Since
these proteins could function as natural tumor suppressors in the
context of cancer, their expression is mostly down-regulated or
even lost in human cancer [40–42] Therefore, novel mechanisms
or molecules which control these feedback regulators should be
worth investigating to ﬁnd novel candidates that might be targeted
in cancer therapy.4. Network expansion
While a large number of human genes and encoded proteins
have been more or less well characterized experimentally, the
function(s) of still the majority of proteins remain mostly elusive.
For example, only some 20% of the human proteins are currently
covered in the KEGG database. However, almost 90% of the pro-
teins contain (predicted) functional domains and are annotated
in the InterPro database accordingly rendering them suitable for
bioinformatic inference of at least some biological function. We
have previously elaborated on the potential of InterPro domain
predictions towards determining pathway membership of the
respective proteins, and utilized this method to bioinformatically
identify novel potential members of signaling pathways for exper-
imental testing [43,44].
Bioinformatic and experimental screening approaches, for
example using RNAi, often identify large numbers of hits that re-quire further validation before the respective genes and proteins
can be regarded functionally characterized in the context of the
biological question under investigation. The placing of individual
proteins into their cellular context requires several pieces of infor-
mation to have available. The subcellular localization of the protein
is often the ﬁrst functional information, and can be obtained by
overexpressing the protein in fusion, for example, with the green
ﬂuorescent protein (GFP). Using high-resolution ﬂuorescence
microscopy often uncovers the cellular compartment(s) a protein
localizes to and is thus likely to convey its function in and further
deﬁnes the repertoire of potentially interacting proteins. While
static localization within ﬁxed cells had been mostly applied in
early studies [45], live-cell imaging is becoming the method of
choice in order to study also the dynamic behavior of individual
proteins and the phenotypes that are induced. Unraveling pro-
tein–protein interactions are a natural next step in the functional
characterization of proteins. This was initially done in high
throughput mostly using yeast two-hybrid systems [46,47], how-
ever, more recently tandem afﬁnity puriﬁcation (TAP) with subse-
quent mass spectrometry (MS) analysis of putative interactors has
led to a tremendously improved knowledge of a number of multi-
protein complexes [48,49]. All these methodologies are able to
identify novel protein–protein interactions, yet these need to be
conﬁrmed and further analyzed to also catch the subcellular distri-
bution and dynamics of protein interactions and protein com-
plexes. There, cross correlation spectroscopy holds the promise to
deliver qualitative and quantitative data as interactions can be
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information on the analyzed proteins [50].
5. miRNAs tune the ERBB-signaling network
MicroRNAs (miRNAs), which are non-protein coding single
stranded 22 nucleotide RNAs, are recently identiﬁed regulators of
gene expression having a broad spectrum of genes they target. It
has been shown that miRNAs can function as tumor suppressor
or oncogenes in the context of cancer (reviewed in [51]) and there
have already several miRNAs been identiﬁed regulating the expres-
sion of ERBB receptors [52]. Very recently, it has been demon-
strated that miR-7 inhibits EGFR and its downstream signaling
intermediate, Raf1, and also leads to a reduced activation of AKT
and ERK1/2 signaling [53]. Phenotypically, miR-7 overexpression
induced cell cycle arrest and cell death in lung carcinoma cells
[53] and decreased cell viability and invasiveness of a glioblastoma
cell line [54]. In another study, Scott et al. [52] showed that miR-
125a/miR-125b inhibit both ERBB2 and ERBB3 receptors in breast
carcinoma cell lines and these authors further observed a reduction
at both AKT and ERK1/2 signaling. This was associated with re-
duced invasion and migration capacities of cells overexpressing
either miR-125a or miR-125b. In addition, miR-128b has been
found to regulate EGFR expression directly in a study that investi-
gated the role of miRNAs in response to the EGFR-targeting drug
geﬁtinib/Iressa in NSCLC [55]. Weiss and co-workers found that
loss of heterozygosity (LOH) of miR-128b is common in tumors
and signiﬁcantly correlated with the clinical response and patient
survival following drug treatment. This study and others have
paved the way towards using miRNA signatures of cancer cells to
predict the response of patient populations to the ERBB-family
receptor’s targeting drugs.
Furthermore, considering the substantial role of miRNAs in
development and other biological processes, miRNAs regulating
ERBB signaling should also be extended to the network level by
integrating relevant miRNAs to the known ERBB network. Several
miRNA target prediction algorithms have been developed based
on the complementarity between the 50 seed region of miRNAs
(residues 2–8) and the 30-UTRs of the respective mRNAs, phyloge-
netic conservation of target sites within the 30-UTRs, and thermo-
dynamic parameters and three-dimensional structures of both
miRNA and target mRNA (reviewed in [56]). Although these pre-
diction algorithms help researchers obtain a ﬁrst impression on
the possible targets of their miRNA of interest, currently available
target prediction databases should be further improved, especially
for coverage of mammals. Based on stringent predictions, miRNAs
should be integrated into protein networks to elucidate how the
proteins and miRNAs regulate the expression of one another from
ﬁne-tuning to stronger effects and provide a better view of the bio-
logical basis of biological processes and human pathogenesis. At
this point, it should also be noted that genes regulated by single
miRNAs or miRNA families could well be functionally related or in-
volved in the same pathway. For example, the miR-2 family has
been shown to regulate several proapoptotic genes and miR-7 col-
lectively regulates genes of the Notch pathway [57]. Therefore,
miRNA target prediction databases should be used together with
databases linking a given gene to a certain biological pathway in
order to help integrate miRNAs and gene networks in a more ro-
bust manner.6. From functional genomics/proteomics via systems biology to
translational research
Most of the information in functional genomics and systems
biological analysis is gathered using in vitro systems, i.e. predom-inantly analyzing the respective biological processes in cell-line
models. However, any cell-line system suffers from the fact that
the conditions and environment of a cell line does not fully match
the natural environment the respective cell line had been derived
from, and that alterations in its genomic, transcriptomic and pro-
teomic repertoire accumulate with extended passaging. Such alter-
ations are reﬂected by mutations and small or larger genomic
rearrangements [58] as well as directed and stochastic changes
in gene expression due to missing cooperation between the respec-
tive cells and otherwise present cells of the (micro-) environment
within tissues, organs, and organisms (like ﬁbroblasts, immune
cells, and blood vessels). Hence, ﬁndings made in in vitro systems
require validation utilizing in vivo models to conﬁrm their rele-
vance. Initially this may be mouse or other model systems (C. ele-
gans, Drosophila, zebraﬁsh), however, disease-relevant information
is best conﬁrmed in the species the respective disease system shall
be investigated. In our case this has been human breast cancer and
we consequently aim to match in vitro data with information ob-
tained in biopsies, tumor material and serum samples of breast
cancer patients. There, receptor status, activation states of proteins
within the ERBB-signaling pathway, as well as the levels of rele-
vant growth factors and hormones provide meaningful informa-
tion on the respective parameters in patients, and permit
correlations to be made with treatment schemes and the clinical
outcome of patients. In addition to the proteins, correlation be-
tween miRNA expression and targeted proteins in the patient sam-
ples and patient survival are being investigated. Special
importance should be given to the problem of de novo and ac-
quired resistance to drugs that are in clinical use (especially for
the treatment of EGFR or ERBB2 overexpressing patients) in order
to ﬁnd alternative protein or miRNA targets or combinations there-
of. The hope is there to identify speciﬁc tumor parameters and
treatment conditions that shall beneﬁt the particular fraction of
patients reﬂecting the necessity of personalized medicine
approaches.7. Perspectives
ERBB receptor signaling has a central role in the development
and progression of several tumor entities and has been the focus
of targeted therapy for over a decade. Although successful to some
extent, there is still a need to improve the effectiveness of drugs
applied to target these receptors, especially in case of development
of resistance. For this reason, recent studies are focusing on combi-
natorial targeting of molecules to overcome the by-pass mecha-
nisms tumor cells have or develop. Along this line, a network
level understanding will help to ﬁnd out the fragile points in the
robust and redundant ERBB protein network. To cover all potential
target strategies, gene or protein networks should be extended to
also include miRNAs as well as epigenetic regulation so that a bet-
ter picture of how the biological processes are regulated. At this
point, recent technologies developed in the functional genomics
and proteomics ﬁelds should be more efﬁciently applied, as we
have discussed in this minireview, to provide high quality and
quantity data to feed into systems biology studies. These ap-
proaches have the potential to provide scientists and clinicians
with better candidates or targeting approaches that will be more
beneﬁcial to relevant patient populations and, hence, improve
the quality of life as well as save tax payer money.
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